Levetiracetam Tarbis

Levetiracetam, the active ingredient in Levetiracetam Tarbis, is an anticonvulsant presented as an oral tablet for oral use. It is used to treat epilepsy, including partial seizures and generalized tonic‑clonic seizures, in adult and pediatric patients as prescribed by a healthcare professional.

GNH USA supplies Levetiracetam Tarbis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and distribution. Customers benefit from reliable supply chains and responsive technical support.

Levetiracetam is an antiepileptic medication that acts on synaptic vesicle protein SV2A to reduce neuronal hyperexcitability, thereby helping to control various seizure types.

- Epilepsy: provides broad seizure control across multiple seizure types. - Partial seizures: reduces frequency and severity of focal onset seizures. - Generalized tonic‑clonic seizures: prevents occurrence of bilateral convulsive episodes. - Adjunct therapy: can be added to other antiepileptics when monotherapy is insufficient.

Levetiracetam may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness - Fatigue - Somnolence - Headache - Irritability - Nausea

Serious or Rare Side Effects: - Severe skin reactions such as Stevens‑Johnson syndrome - Depression or emergence of suicidal thoughts - Blood dyscrasias including neutropenia or thrombocytopenia - Multi‑organ hypersensitivity syndrome - Severe allergic reactions with angioedema - Hepatic injury (rare)

When prescribing levetiracetam, clinicians should consider several precautionary measures to ensure safe use. - Renal impairment: adjust dose based on creatinine clearance. - Hepatic dysfunction: monitor liver function tests regularly. - Pregnancy: risk unknown; use only if benefit outweighs potential risk. - Abrupt discontinuation: taper gradually to avoid seizure worsening. - Concomitant CNS depressants: use with caution due to additive sedation. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Levetiracetam can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Carbamazepine: strong enzyme inducer that markedly reduces levetiracetam plasma levels. - Phenytoin: induces metabolism, potentially decreasing seizure control. - Phenobarbital: enhances clearance, leading to subtherapeutic concentrations.

Moderate Interactions (Monitor Closely): - Valproic acid: may increase levetiracetam levels, requiring dose adjustment. - Alcohol: can potentiate central nervous system depression and dizziness.